Semaglutide Weight Management and Cardiovascular Risk Reduction
Phase 3 trial programme for oral semaglutide 50 mg in
overweight or obesity, OASIS
Oral semaglutide characteristics
a
Oral semaglutide 50mg:
Semaglutide tablets in overweight
or obesity
•
Once daily tablet
Phase 3a programme with oral
semaglutide 50 mg
Aims to confirm efficacy and safety
Submission in US and EU expected
during 2023
The global launch of oral
semaglutide 50 mg is contingent on
portfolio prioritisations and
manufacturing capacity
BW: Body weight; T2D: Type 2 diabetes
Focused phase 3 trial programme
OASIS 1
.
667 patients
50 mg dose
68 week
Primary endpoint: BW %
198 patients incl. T2D
OASIS 2
.
EAST ASIA
•
68 week
OASIS 3
China
• Primary endpoint: BW %
•
.
200 patients incl. T2D
44 week
Primary endpoint: BW %
OASIS 4
25 mg dose
2022
⚫ 300 patients
64 week
Primary endpoint: BW %
2023
2024
2025View entire presentation